Nagoya University · Medicine
Professor Masamichi Hayashi's research lab specializes in molecular oncology and cancer biomarker discovery, with a focus on identifying epigenetic and genetic alterations underlying hepatocellular carcinoma (HCC) and pancreatic cancer. The lab investigates tumor suppressor genes such as AKAP12 and COL1A1, exploring their roles in cancer progression through promoter hypermethylation and gene expression regulation. A key research direction involves translating molecular findings into clinical applications, such as using gene methylation profiling of surgical margins to predict recurrence and guide surgical decision-making in head and neck cancers. The lab bridges basic molecular research with translational medicine to improve patient outcomes through precision oncology strategies.
Figures are computed from collected data and may differ slightly.
Pancreatic cancer frequently metastasized to distant LNs via a complex pathway and developed into systemic disease. Aggressive multimodality therapy, including neoadjuvant therapy, is essential to improve the long-term survival of patients at substantial risk of distant LN metastasis.
Triple-combination array analysis successfully identified COL1A1 as a candidate survival-related gene in HCCs. Epigenetic down-regulation of COL1A1 mRNA expression might have a role as a prognostic biomarker of HCC.
A panel of gene methylation targets in deep surgical margin imprints provides a potential predictive marker of postoperative locoregional recurrence. Intraoperative use of molecular margin imprint analysis may assist surgeons in obtaining rigorously negative surgical margins and improve the outcome of head and neck surgery.
The current data suggest that AKAP12 is downregulated in cancer tissues through promoter hypermethylation, and may have a role as a candidate tumor suppressor gene for HCC.
Open papers in the app to read, cite, and organize with AI.
